DrugPatentWatch Database Preview
Drugs in Development Information for OTO-104
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug OTO-104?
OTO-104 is an investigational drug.
There have been 23 clinical trials for OTO-104.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.
The most common disease conditions in clinical trials are Meniere Disease, Otitis, and Otitis Media. The leading clinical trial sponsors are Otonomy, Inc., Assiut University, and OHSU Knight Cancer Institute.
There are two US patents protecting this investigational drug and forty-two international patents.
Summary for OTO-104
| US Patents | 2,545 |
| International Patents | 42,697 |
| US Patent Applications | 4,497 |
| WIPO Patent Applications | 2,808 |
| Japanese Patent Applications | 17 |
| Clinical Trial Progress | Phase 3 (2013-11-01) |
| Vendors | 69 |
Recent Clinical Trials for OTO-104
| Title | Sponsor | Phase |
|---|---|---|
| OTO-413 in Subjects With Speech-in-Noise Hearing Impairment | Otonomy, Inc. | Phase 1/Phase 2 |
| OTO-313 in Subjects With Subjective Tinnitus | Otonomy, Inc. | Phase 1/Phase 2 |
| Phase 3 Study of OTO-104 in Subjects With Unilateral Meniere's Disease | Otonomy, Inc. | Phase 3 |
Clinical Trial Summary for OTO-104
Top disease conditions for OTO-104
Top clinical trial sponsors for OTO-104
US Patents for OTO-104
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| OTO-104 | Start Trial | IBAT inhibitors for the treatment of liver diseases | Albireo AB (Gothenburg, SE) | Start Trial |
| OTO-104 | Start Trial | Methods and compositions for producing hepatocyte-like cells | The Board of Trustees of the Leland Stanford Junior University (Stanford, CA) | Start Trial |
| OTO-104 | Start Trial | Low, immune enhancing, dose mtor inhibitors and uses thereof | Novartis AG (Basel, CH) | Start Trial |
| OTO-104 | Start Trial | Salts of an epidermal growth factor receptor kinase inhibitor | Celgene CAR LLC (Pembroke, BM) | Start Trial |
| OTO-104 | Start Trial | 1-(4-pyrimidinyl)-1H-pyrrolo[3,2-c]pyridine derivatives as NIK inhibitors | Janssen Pharmaceutica NV (Beerse, BE) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for OTO-104
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| OTO-104 | Australia | 2011326871 | 2030-11-08 | Start Trial |
| OTO-104 | Brazil | 112013010157 | 2030-11-08 | Start Trial |
| OTO-104 | Canada | 2815749 | 2030-11-08 | Start Trial |
| OTO-104 | China | 103260625 | 2030-11-08 | Start Trial |
| OTO-104 | China | 105288580 | 2030-11-08 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
